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Abstract
The leishmaniases are infectious diseases caused by a number of species of obligate intracellular protozoa of the genus 
Leishmania with disease manifesting as cutaneous, mucocutaneous and visceral forms. Despite being endemic in more than 
80 countries and its being the cause of high morbidity and mortality, leishmaniasis remains a neglected tropical disease. 
Chemotherapy is the frontline treatment, but drugs in current use suffer from toxic side effects, difficulties in administration 
and extended treatment times — moreover, resistance is emerging. New anti-leishmanial drugs are a recognised international 
priority. Here, we review investigations into N-myristoyltransferase (NMT) as a potential drug target. NMT catalyses the 
co-translational transfer of a  C14 fatty acid from myristoyl-CoA onto the N-terminal glycine residue of a significant subset 
of proteins in eukaryotic cells. This covalent modification influences the stability and interactions of substrate proteins with 
lipids and partner proteins. Structure-guided development of new lead compounds emerging from high-throughput screening 
campaigns targeting Leishmania donovani NMT has led to the discovery of potent inhibitors which have been used to gain 
insights into the role of protein myristoylation in these parasites and to validate NMT as a drug target.
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Introduction
The leishmaniases are diseases caused by more than 20 
different Leishmania parasite species (Burza et al. 2018; 
Sasidharan and Saudagar 2021). The three main forms of 
the disease are visceral leishmaniasis (VL) which is the most 
serious and often fatal if untreated, cutaneous leishmaniasis 
(CL) which is the most common and is associated with dis-
figuring skin lesions and mucocutaneous leishmaniasis in 
which the mucous membranes of the nose, mouth and throat 
are partially or totally destroyed. According to the World 
Health Organization (www. who. int/ health- topics/ leish mania 
sis), more than 1 billion people live in areas where leishma-
niasis is endemic, and it is estimated there are 30,000 and 
1 million new cases, respectively, of VL and CL annually 
occurring mainly in South America, East Africa, the Middle 
East and the Indian subcontinent.
Leishmania parasites are transmitted to human and other 
mammalian hosts through the bite of a female phlebotomine 
sandfly when it takes a blood meal. The promastigote form 
of the parasite which is injected into the skin is taken up 
by macrophages, or other mononuclear phagocytes, where 
it becomes enclosed in a phagosome that fuses with lys-
osomes to form a parasitophorous vesicle (PV). In the PV, 
the parasite undergoes differentiation to the amastigote form. 
Amastigotes multiply in the PV before bursting from the 
cell to initiate new cycles of infection of cells located either 
in the immediate neighbourhood in the case of CL or after 
dissemination to distant tissues such as the liver, spleen and 
bone marrow in the case of VL.
In the absence of a licenced vaccine, measures to coun-
ter leishmaniasis rely on chemotherapy (Burza et al. 2018; 
Sasidharan and Saudagar 2021). Current treatments include 
pentavalent antimonials such as sodium stibogluconate, 
amphotericin B, miltefosine, paromomycin and pentamidine 
(Fig. 1). Treatments suffer variously from the need for hospi-
talisation and monitoring, toxic side effects, prolonged treat-
ment times and high costs. Moreover, poor diagnosis and 
complex co-infections diminish the effectiveness of therapy 
and the lack of oral formulations complicates delivery and 
reduces compliance. The effectiveness of therapy is further 
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compromised by the frequency of relapse and the emergence 
of drug resistance.
The use of antimony (Sb)-containing compounds has 
dominated the treatment of leishmaniasis for a century or 
so despite the need for parenteral administration, toxic side 
effects and high costs. More recently, the natural product 
amphotericin B, an anti-fungal agent synthesised by certain 
Streptomyces species, has supplanted sodium stibogluconate 
as the first-line treatment of VL in many parts of the world. 
Its toxic side effects are considerably reduced when it is 
delivered as a liposomal formulation, AmBisome. However, 
it too has to be injected, and again, it is expensive. Miltefo-
sine is a repurposed anti-cancer drug and an alkyl phospho-
choline which can be orally administered for treatment of 
VL, though it is expensive. It too suffers from side effects, 
and significantly, it has been identified as a teratogen which 
limits its suitability. It has a long half-life in the body giving 
rise to concerns that resistance will emerge as the parasites 
are exposed to sub-lethal concentrations of the drug. Mean-
while, paromomycin, an aminoglycoside antibiotic which 
has been repurposed for the treatment of cutaneous leishma-
niasis, is applied topically as an ointment. Pentamidine is an 
aromatic diamidine often used to treat CL which is thought 
to have a mitochondrial site of action. For all of the drugs, 
little is known of the target(s), the mechanism of action or 
the mechanism of resistance.
N‑myristoyltransferase and protein 
myristoylation in Leishmania
The enzyme N-myristoyltransferase (NMT) catalyses the 
transfer of the  C14 fatty acid, myristate, from myristoyl-
CoA onto the N-terminal glycine residue of a subset of 
cellular proteins (Meinnel et al. 2020). N-myristoylation 
of proteins typically takes place co-translationally follow-
ing the action of methionine aminopeptidase on nascent 
peptides emerging from the exit tunnel of the ribosome. 
Lipidation has been shown to influence the stability of pro-
teins and to determine their partitioning into membranes 
as part of protein trafficking and localisation. It can also 
shape their interactions with protein partners. NMT is a 
50-kDa monomeric protein. There is a single NMT in pro-
tozoan parasites in contrast to the two, NMT1 and NMT2, 
present in the human host.
The specificity and mechanism of the NMTs from Can-
dida albicans, Saccharomyces cerevisiae and most recently 
human NMT1 have been studied in great detail (Bhatna-
gar et al. 1998, 1994; Dian et al. 2020; Lodge et al. 1994; 
Rudnick et al. 1991), and it is assumed that knowledge of 
these enzymes carries over to the enzymes from parasites. 
Although the sequences of the parasite NMTs share only 
40–45% sequence identity with their fungal and human 
orthologues, the sequence conservation is much higher in the 
active site. Reaction proceeds via a compulsory order mech-
anism (Fig. 2A) with binding of myristoyl-CoA preceding 
that of the substrate protein, and following acyl transfer via 
a nucleophilic addition–elimination reaction (Fig. 2B), CoA 
release precedes dissociation of the acylated protein (Rud-
nick et al. 1991). The structures of NMT from L. donovani 
and L. major (Brannigan et al. 2010; Frearson et al. 2010) 
feature a characteristic 12-stranded twisted β-sheet which 
provides the base of an extended groove. The left-hand half 
of the groove as shown in Fig. 2C forms the binding site for 
myristoyl-CoA with the right-hand half forming a binding 
site for the amino terminal peptide segment of the substrate 
protein or, as in Figs. 2C and D, a peptidomimetic inhibitor 
(Olaleye et al. 2014). The α-carboxylate at the C-terminus of 
the protein resides at the heart of the structure. It plays a key 
role in catalysis, acting as a base to deprotonate the α-amino 
Fig. 1  Chemical structures of a 
selection of clinically important 
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Fig. 2  Structure and ligand binding to Leishmania NMT. A Scheme 
showing the ordered binding of substrates and the ordered release of 
products in the NMT-catalysed reaction. B Key step in the catalytic 
mechanism. Following binding of the substrates and deprotonation of 
the substrate protein’s α-amino group by the carboxylate of Leu421, 
there is nucleophilic attack of the amino group of the glycine on the 
carbonyl carbon of the thioester of myristoyl-CoA. C The crystal 
structure of the ternary complex of NMT from L. major (PDB code 
4c7h) with myristoyl-CoA and a peptidomimetic inhibitor bound in 
the active site. The protein is represented as a ribbon colour-ramped 
from the N-terminus (blue) to the C-terminus (red). The C-terminus 
is additionally labelled with an asterisk. The ligands are shown in 
sphere representation with atoms coloured by type: carbon, grey for 
peptidomimetic and green for myristoyl-CoA; oxygen, red; nitrogen, 
blue; sulphur, yellow; phosphorus, magenta. D Lower, zoom view 
of C with electrostatic surface rendering of the protein molecule 
emphasising the substrate binding groove. Upper, chemical struc-
ture of the peptidomimetic inhibitor (N-(10-aminodecyl)-L-seryl-N-
(2-cyclohexyl)-L-lysinamide). E Structures of inhibitor molecules 
described in the text. In the centre, these molecules are displayed 
following least squares superposition of the protein Cα atoms in the 
respective structures of the LmNMT-myristoyl-CoA inhibitor ter-
nary complexes. The inhibitors occupy overlapping volumes in the 
peptide-binding cavity. The inhibitors are coloured: aminoacylpyr-
rolidine, grey; pyrazolyl sulfonamide, blue; piperidinylindole, coral; 
quinoline, ice blue; thienopyrimidine, green; biphenyl, red
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group on the protein substrate for nucleophilic attack on the 
carbonyl carbon of the thioester of myristoyl-CoA (Fig. 2B).
ADP-ribosylation factor-like proteins and the hydrophilic 
acylated surface proteins were among the first myristoylated 
proteins to be identified in Leishmania though it was antici-
pated that the repertoire of myristoylated proteins would be 
much broader (Denny et al. 2000; Sahin et al. 2008). The 
absence of a clear myristoylation consensus sequence ham-
pered the identification of NMT substrates. A fuller reper-
toire has been defined by metabolic labelling in vivo with 
an alkyne-functionalised myristic acid. Downstream click 
chemistry was then used to couple the fatty acid–acylated 
proteins to an azide-capture reagent containing biotin and a 
fluorophore (Wright et al. 2014). Mass spectrometry of the 
enriched and gel-electrophoretically resolved protein set led 
to the identification of 30 high-confidence NMT substrates 
in L. donovani with roles in protein phosphorylation, pro-
tein transport and degradation. The role of myristoylation in 
diverse regulatory functions suggests that NMT is an essen-
tial enzyme in Leishmania and therefore a rational target for 
the development of new therapeutics targeting leishmaniasis. 
Supporting this notion, NMT has been shown to be essential 
in the protozoan parasites, T. brucei, T. cruzi and P. falcipa-
rum, using both genetic and chemical methods (Brannigan 
and Wilkinson 2016; Frearson et al. 2010; Herrera et al. 
2016; Schlott et al. 2018; Wright et al. 2014).
Discovery of L. donovani NMT inhibitors
The springboard to the discovery of inhibitors of NMT from 
L. donovani (LdNMT) was a high-throughput screen car-
ried out with 150,000 selected compounds from the Pfizer 
Global Diversity Representative Set which included legacy 
compounds from anti-fungal NMT programmes (Bell et al. 
2012). A scintillation proximity assay was carried out for 
LdNMT in parallel with a screen against NMT from P. fal-
ciparum with promising compounds subsequently assayed 
for activity against NMT1 and NMT2 from the human host. 
This led to the identification of four novel series of com-
pounds with submicromolar  IC50 values (0.1–1μM) against 
LdNMT and 10–700-fold selectivity over the human ortho-
logues (Bell et al. 2012).
To guide the downstream medicinal chemistry cam-
paign, crystal structures were determined of complexes of 
L. major NMT, which has 97% sequence identity to L. dono-
vani NMT, with representative compounds from the four 
series (Fig. 2E) (Brannigan et al. 2014). These structures 
were compared with those of LmNMT complexes of a potent 
pyrazolyl sulphonamide inhibitor of T. brucei NMT (Frear-
son et al. 2010) and a quinoline inhibitor of P. vivax NMT 
(Goncalves et al. 2017) (Fig. 2E). In ternary complexes with 
myristoyl-CoA, these inhibitors occupy overlapping volumes 
in the peptide-binding groove.
The thienopyrimidine (Fig. 2E and 3A) inhibitor has 
an  IC50 value of 0.25μM and tenfold selectivity over the 
human NMT isoform 1 (HsNMT1). Unexpectedly, two 
molecules occupy the binding site with their bicyclic aro-
matic rings stacking against each other (Bell et al. 2020; 
Brannigan et al. 2014). The higher affinity ligand (lower 
left in Fig. 3A) binds in a proximal site with its tertiary 
amine forming a salt-bridge to the main chain carboxylate of 
the enzyme’s C-terminal residue Leucine 421. The weaker 
binding ligand (upper right in Fig. 3A), as evidenced by 
its poorer associated electron density and its higher atomic 
temperature factors, is distally located (Brannigan et al. 
2014). The piperidinylindole (Figs. 2E and 3C) has a Ki of 
250 nM against LdNMT and > 100-fold selectivity against 
HsNMT1. In the binding site, this inhibitor wraps around the 
side chain of Phe90 with its two six-membered rings packing 
onto opposite faces of the aromatic ring of the side chain 
(Fig. 3C). The piperidine ring nitrogen forms an ion-pair 
with the α-carboxylate of the C-terminal residue Leu421.
The aminoacylpyrrolidine hit (Fig. 2E) was identified 
through analogue screening of the primary high-through-
put screening hit explaining its low  IC50 value of 0.08μM 
against LdNMT. It has a selectivity factor of ~ 80. The crys-
tal structure of the aminoacylpyrrolidine complex resolved 
a stereochemical ambiguity (the two enantiomers exhibit-
ing  IC50 values of 0.025μM and 1.7μM) and revealed the 
inhibitor to be bound in a conformation that can be described 
as hydrophobically collapsed (Brannigan et al. 2014). The 
folding of the inhibitor directs its centrally located primary 
amine towards the myristoyl-CoA where it makes contacts 
with catalytically important residues and a conserved water 
molecule (Fig. 3B).
Comparison of the structures showed significant overlap 
in the volumes occupied by the aminoacylpyrrolidine and 
piperidinylindole inhibitors with overlap of one of the chlo-
rophenyl moieties of the former with the indole ring of the 
latter (Brannigan et al. 2014; Hutton et al. 2014) (Fig. 3D). 
This suggested the possibility of synthesising a hybrid mol-
ecule. As shown in Fig. 3D, the resulting hybrid inhibitor 
exhibited a Ki of 1.6 nM for LdNMT which is 40-fold and 
150-fold higher than the Ki values of the parent molecules. 
It can be seen in the crystal structure that the hybrid, or 
merged, inhibitor picks up on the binding mode of both par-
ent molecules (Fig. 3D) such that all of the key interactions 
with the enzyme are conserved. This presents a nice example 
of this approach (Zhang et al. 2019). In this case, however, 
there is a trade-off as the gain in potency is offset by a sig-
nificant loss of selectivity (selectivity factor reduced to 17) 
with respect to HsNMT (Hutton et al. 2014). The knowledge 
gained in these studies was later used in the development 
of potent inhibitors of human N-myristoyltransferase that 
1142 Biophysical Reviews (2021) 13:1139–1146
1 3
block capsid assembly and replication of the common cold 
virus. In this study, rather than merging overlapping binding 
modes, fragments discovered to bind in neighbouring vol-
umes were merged leading to spectacular gains in potency 
(Mousnier et al. 2018).
Validation of NMT as a drug target 
in Leishmania
Gene deletion studies showed that it was possible to obtain 
parasites with single but not double knock-outs of the NMT 
gene in L. donovani promastigotes, effectively demonstrat-
ing that NMT is essential to parasites in this life cycle stage 
(Brannigan et al. 2010). For therapeutic purposes, it is neces-
sary to kill the intracellular amastigotes, and therefore, it is 
important to establish that the target protein is essential to 
this life cycle stage. For NMT, this was established using a 
more elaborate plasmid shuffle approach (Paape et al. 2020). 
Here, parasites with both copies of the NMT gene deleted 
were generated following transfection with a plasmid har-
bouring a functioning copy of the NMT gene and a gene 
encoding thymidine kinase (TK). Upon treatment with the 
nucleoside analogue, ganciclovir, the presence of the TK 
gene provides a means of negative selection for the plas-
mid. This is because following TK-mediated phosphoryla-
tion of ganciclovir, the resulting nucleotide interferes with 
DNA strand elongation during replication, leading either to 
cell death or forcing expulsion of the plasmid. Ganciclo-
vir treatment of mice that had established infections with 
amastigotes and later analysis of the spleen parasite burden 
and composition showed that NMT is indeed essential for 
the viability of intracellular amastigotes (Paape et al. 2020).
In a chemical validation approach, metabolic tagging 
of NMT substrates in both promastigotes and amastigotes 
was achieved using an alkyne mimetic of myristic acid as 
described above (Wright et al. 2015). As well as allowing 
definition of the complement of NMT substrates in the L. 
donovani life cycle stages, this methodology provided an 
assay of in vivo target engagement by NMT inhibitors. The 
LdNMT Ki = 63 nM
HsNMT Ki = 2,100 nM
LdNMT Ki = 254 nM
HsNMT Ki = 28,500 nM
LdNMT Ki = 1.6 nM
HsNMT Ki = 27 nM
A B C
D
Fig. 3  The structure of the inhibitor binding pocket and protein–
inhibitor interactions. A The thienopyrimidine (PDB Entry, 4cgo), B 
the aminoacylpyrrolidine (4cgn) and C the piperidinylindole (4cgm) 
ligands are shown in cylinder representation with grey carbon atoms 
with the surrounding protein in ball-and-stick and green carbon 
atoms. The myristoyl-CoA cofactor, which is situated to the left of 
the ligand in each case, has been omitted for clarity. D Hybridisation 
of the binding modes of the aminoacylpyrrolidine (grey carbons) and 
piperidinylindole inhibitors (coral carbons) to generate a more potent 
hybrid NMT inhibitor (magenta carbons). Other atoms are coloured 
by type: oxygen, red; nitrogen, blue; chlorine, white; fluorine, cyan
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study explained a disparity in the properties of a pair of 
pyrazole sulphonamide inhibitors related to the molecule 
shown in Fig. 2. Both exhibit similar (2.5-fold difference) 
nanomolar potencies in enzyme inhibition, but there is a 
50-fold difference in their EC50 against ex vivo amastigotes. 
Using in vivo alkyne tagging, the study showed that parasite 
cell killing (EC50) correlated with inhibition of in vivo tag-
ging, validating NMT as a drug target. However, even for the 
better acting inhibitor, the translation from in vitro enzyme 
inhibition (Ki) to in vivo enzyme inhibition and cell killing 
(EC50) was poor (EC50/Ki = 25). The authors concluded that 
the inhibitor was not efficiently accessing its target.
In other work, a cosmid-based overexpression library 
screening approach was taken towards the pharmacological 
validation of a lead compound as a drug target in L. donovani 
(Corpas-Lopez et al. 2019). The study concerned a potent 
pyrazole sulphonamide inhibitor of LdNMT (Ki = 0.34 nM) 
that had only modest activity against L. donovani intracellu-
lar amastigotes (EC50 = 2.4μM). Parasites transfected with a 
high-coverage representative bar coded cosmid library were 
grown for 12 days in the presence of the inhibitor at a con-
centration twofold above the EC50. Isolation and sequenc-
ing of the cosmids maintained in the resistant population 
showed enrichment of fragments containing the gene encod-
ing LdNMT consistent with specific targeting of the enzyme 
by the pyrazole sulphonamide. Confirming this interpreta-
tion, the overexpression of LdNMT in promastigotes led to 
a tenfold reduction in sensitivity to this inhibitor (Corpas-
Lopez et al. 2019). In a complementary approach, thermal 
proteome profiling showed that the same inhibitor stabi-
lises LdNMT against heat denaturation in parasite lysates, 
again suggesting on-target engagement (Corpas-Lopez et al. 
2019). Consistent with these encouraging indicators, oral 
dosing of this compound in a mouse model of VL led to a 
50% reduction in parasite burden.
Conclusions and future prospects
The NMT inhibitors discovered by high-throughput screen-
ing approaches to date have been competitive ones which 
exclusively occupy the peptide-binding site rather than the 
fatty acyl-CoA binding site. Myristoyl-CoA binds to NMT 
with ~ 100-fold higher affinity (Johnson et al. 1994) than 
peptide substrates; moreover, its binding site is more highly 
conserved between the parasite and host NMTs. Fatty acyl-
CoAs are shared substrates with other cellular enzymes 
which would present a specificity challenge. The latter con-
cern could be overcome using a covalent inhibitor strategy as 
has been applied successfully in targeting the ATP binding 
sites of protein kinases (Zhao and Bourne 2018).
Despite the achievement of high potency inhibitors 
of NMT from Leishmania species by structure-guided 
medicinal chemistry and the development of sophisticated 
assays of NMT function and inhibition in vivo, we and oth-
ers have been unable to design inhibitors that kill parasites 
inside macrophages at reasonable therapeutic doses. This 
is striking as many of the compounds generated in these 
studies exhibit on-target activity in P. falciparum-infected 
red blood cells and P. berghei infected mice and even in 
the targeting of human NMT1 as a strategy to counter 
human rhinovirus infection (Mousnier et al. 2018; Wright 
et al. 2014). The failure of our Leishmania NMT inhibitors 
may be due to their limited uptake by the amastigote stage 
parasites which bear glycoinositolphospholipid coats and 
reside within a parasitophorous vacuole in the host cell 
(Novozhilova and Bovin 2010). It may yet prove possible 
to introduce the right chemistry for parasite cell access 
into leads emerging from alternative screens.
To identify components of other post-translational 
modification systems with potential as drug targets, Mot-
tram and co-workers have been systematically knocking 
out genes encoding protein kinases and protein ubiqui-
tination/deubiquitination system factors in L. mexicana. 
They found scores of genes for which null mutants could 
not be generated and which are likely to be essential in the 
promastigote stage (Baker et al. 2021; Burge et al. 2020; 
Damianou et al. 2020). To allow identification of genes 
needed for differentiation to the human infectious para-
site forms, their CRISPR-Cas9 repair cassettes included a 
unique 12-nucleotide barcode. Following pooling of sets 
of null mutants and growth and differentiation under dif-
ferent regimes, the surviving parasite population was char-
acterised using next-generation sequencing. This parallel 
phenotyping assay revealed a number of genes whose dele-
tion leads to strong defects in amastigote differentiation, 
macrophage infectivity and capacity to survive in mice 
following footpad injection (Baker et al. 2021; Burge et al. 
2020; Damianou et al. 2020). These genes warrant further 
investigation as promising future protein targets for anti-
leishmanial drug discovery.
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